IDIX News 5.46 Idenix Pharmaceuticals (IDIX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Idenix Pharmaceuticals (IDIX) 5.46 $IDIX

Idenix Pharmaceuticals Has Returned 11.7% Since SmarTrend Recommendation (IDIX)
Comtex SmarTrend(R) - Fri Apr 11, 11:17AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 2 weeks, Idenix Pharmaceuticals has returned 11.75% as of today's recent price of $5.56.

Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.

Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:

Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.

Why Idenix Pharmaceuticals, B&G Foods, and Petrobras Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 07, 7:02PM CDT
Last week's memories of near-record closes for the Dow Jones Industrials faded further into the background Monday, as the Dow posted a decline of more than 1% amid growing concerns about the market's valuation. Even though more volatile sectors of...

MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...

Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Why Idenix Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 12:12PM CDT
What: Shares of Idenix Pharmaceuticals , a clinical-stage biopharmaceutical company developing therapies to treat human viral diseases, jumped as much as 14% after reporting data and updating the progress of its nucleotide prodrug inhibitor...

Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C
GlobeNewswire - Mon Apr 07, 6:06AM CDT
-- Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437

52.5% Return Seen to Date on SmarTrend Idenix Pharmaceuticals Call (IDIX)
Comtex SmarTrend(R) - Tue Mar 25, 9:14AM CDT
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 5 months, Idenix Pharmaceuticals has returned 52.54% as of today's recent price of $6.75.

Idenix Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibitor (Samatasvir) Poster Presentations at 49th Annual Meeting of the European Association for the Study of the Liver
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company's nucleotide prodrug, IDX21437, and for samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, at The International Liver Congress(TM) 2014, the 49th annual meeting of the European Association for the Study of the Liver (EASL), taking place in London, April 9-13, 2014. Full abstracts can now be viewed at the EASL Congress website.

Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case
GlobeNewswire - Mon Mar 24, 6:01AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it intends to file an appeal to challenge the Oslo, Norway District Court's (the "Court" decision in a patent invalidity case concerning Idenix's co-owned Norwegian patent NO 330 755 that covers certain 2'-methyl-2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus (HCV) and other flaviviridae infections.

Geron Held Up
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:51PM CDT
After zooming up on positive data for its telomerase inhibitor imetelstat in myelofibrosis and multiple myeloma, Geron came crashing back to earth this month when the biotech announced that the FDA was putting its clinical trial on hold due to...

Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register

Idenix Files Lawsuit vs. Gilead Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:25PM CDT
Idenix files Sovaldi-related patent infringement lawsuit against Gilead

Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 19, 12:27PM CDT
Last week's highlights include Biogen's addition to S&P100, the FDA clinical hold on Geron's sole pipeline candidate and an improved outlook from Alexion.

Top Gainers under Review -- Research on Coeur Mining, Eagle Rock Energy Partners, Idenix Pharma, and WidePoint
PR Newswire - Wed Mar 19, 7:15AM CDT
On Tuesday, March 18, 2014, the US markets saw a positive sentiment with the NASDAQ Composite closing at 4,333.31, up 1.25%, the Dow Jones Industrial Average ending the session at 16,336.19, up 0.55% and the S&P 500 edging 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Coeur Mining Inc. (NYSE: CDE), Eagle Rock Energy Partners L.P. (NASDAQ: EROC), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and WidePoint Corp. (AMEX: WYY). Free technical research on CDE, EROC, IDIX and WYY can be downloaded upon signing up at:

4 Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 18, 8:41PM CDT
These under-$10 stocks are within range of triggering breakout trades.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 29

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 68

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading

Top 5 Most Recently Viewed Articles

JPMorgan's Jamie Dimon Advocates for Office Work Among Feds

Updated Category News Views 130

JPMorgan's Jamie Dimon Advocates for Federal Employees to Return Jamie Dimon, the CEO of JPMorgan Chase, recently expressed his concerns about the numerous vacant offices in Washington, DC, calling on federal employees to head back to their workplaces. His statements have sparked a lively conversation about remote work and its effects on productivity as well as the...

Continue Reading
South Bow’s Robust Q3 2025 Performance and Future Plans

Updated Category News Views 270

South Bow's Third-Quarter Results & 2026 Projections CALGARY, Alberta, Nov. 13, 2025 -- South Bow Corp. (TSX: SOBO & NYSE: SOBO) has disclosed its financial and operational results for the third quarter of 2025 while providing insights about its outlook for 2026. All figures are presented in U.S. dollars unless noted otherwise. Performance Highlights Operational and...

Continue Reading
Smart Logistics Global Limited Completes Successful IPO Funding

Updated Category News Views 174

Smart Logistics Global Limited Successfully Closes IPO Smart Logistics Global Limited (NASDAQ: SLGB), a distinguished logistics solution provider based in Hong Kong, has recently announced the successful completion of its initial public offering (IPO). Through this offering of 1,000,000 ordinary shares priced at $5.00 each, the company generated a total of $5,000,000,...

Continue Reading
Mobilizing Capital to Achieve Sustainability Goals with UN

Updated Category News Views 196

Mobilizing Capital to Achieve Sustainability Goals with UN The UN Global Compact recently hosted a significant forum where over 50 CEOs and representatives convened to strategize on mobilizing private capital for sustainable and inclusive growth. With leaders from various sectors, the forum emphasized how collaboration between the business community and governmental...

Continue Reading
HASA Inc.'s Strategic Acquisition of Bio-Dex Labs

Updated Category News Views 27

Diving into the Pool Chemical Business What a splash in the world of pool chemicals! HASA Inc., the big kahuna in water treatment solutions, just scooped up Bio-Dex Laboratories, a name known far and wide among pool service pros. We're talking a serious step-up in HASA's game, as they integrate this trusted brand's top-notch products into their already hefty lineup. A...

Continue Reading